New molecular targets for the treatment of neovascular age-related macular degeneration by Tosi, Gian Marco et al.
[page 96]                                                  [Translational Medicine Reports 2017; 1:6819]
New molecular targets for the treatment of neovascular age-relatedmacular degeneration
Gian Marco Tosi,1 Marcella Barbarino,2
Maurizio Orlandini,3
Federico Galvagni3
1Ophthalmology Unit of the Department
of Medicine, Surgery and Neuroscience,
University of Siena; 2Department of
Medicine, Surgery and Neuroscience,
University of Siena, Siena; 3Department
of Biotechnology, Chemistry and
Pharmacy, University of Siena, Siena,
Italy
Abstract
Age-related macular degeneration
(AMD) is a progressive chronic disease that
currently represents the leading cause of
irreversible vision loss in the western world.
Experimental and clinical evidence has
demonstrated that vascular endothelial
growth factor A (VEGF-A) plays an impor-
tant role in promoting the choroidal neovas-
cularization that characterizes the wet form
of AMD. Intravitreal injection of anti-
VEGF-A agents is the current treatment of
choice for neovascular AMD (nAMD).
These agents have brought about dramatic
changes in the treatment of nAMD, but
most patients require frequently repeated
injections and regular long-term follow-up,
with a significant percentage of them show-
ing resistance to anti-VEGF-A drugs. Thus,
the identification of additional therapies
that could improve the treatment protocols
is needed. There are numerous areas of
investigation into new treatments, with
increasing efforts being made to study drugs
that address various targets along the angio-
genic signaling cascade, or other pathways
related to the onset of nAMD. The aim of
the present review is to summarize and dis-
cuss promising new therapies and targets
that have the potential to improve outcomes
and to lengthen treatment durability, espe-
cially in patients with recalcitrant or recur-
rent forms of nAMD.
Introduction
Age-related macular degeneration
(AMD) is the leading cause of blindness in
developed countries and its prevalence and
incidence is likely to increase dramatically
with the aging of the population.1 The
exudative form of AMD, although less com-
mon than the atrophic form, is more threat-
ening to vision: 90% of those with severe
visual loss due to AMD suffer from the
exudative type.
The main pathological feature that char-
acterizes the exudative form of AMD is
choroidal neovascularization (CNV).
Although many aspects of the molecular
pathogenesis of exudative AMD have not
yet been elucidated, experimental and clini-
cal evidence has demonstrated that vascular
endothelial growth factor A (VEGF-A)
plays a central role in promoting CNV.2-4
Intravitreal injection of anti-VEGF-A
agents is the current treatment of choice for
neovascular AMD (nAMD), and five mole-
cules have been introduced into clinical
practice since 2004 (bevacizumab, pegap-
tanib, ranibizumab, aflibercept and a mole-
cule newly approved for the Chinese mar-
ket, conbercept). This has brought about
dramatic changes in the management of the
pathology, but the challenges related to the
treatment of nAMD remain numerous.
Thus, there is a need for efforts to investi-
gate new areas involved in the pathophysi-
ology of neovascularization  (NV) of the
eye. Many fields of interest seem to be
promising: among them, research regarding
new molecular targets involved in the
neoangiogenic pathway, together with
VEGF-A, would appear to have the poten-
tial to bring significant therapeutic
improvements in the near future.
Neoangiogenesis in age-related
macular degeneration
Neoangiogenesis is a physiological
mechanism involved in many embryonic
and adult life processes, such as wound
healing, blood vessels reforming during
menstruation, placenta formation, etc.
Neoangiogenesis may also occur as an
unfavourable phenomenon, as is the case,
for example, with tumor growth, or in phys-
iologically avascular tissues, such as the
cornea, vitreous body or the macular region
of the retina. Two major types of ocular NV
affect the retina: retinal NV, which is the
pathogenetic basis for proliferative diabetic
retinopathy, retinal vein occlusions, and
retinopathy of prematurity; and subretinal
or CNV.5 Subretinal and CNV occur in dis-
eases of the outer retina and Bruch’s mem-
brane, the most prevalent being nAMD.
There is a considerable overlap in the
vasoactive molecules involved in retinal
and CNV, as both result from a functional
dominance of angiogenic factors over
antiangiogenic/angiostatic factors, regard-
less of whether the primary event is an
increase in angiogenic activity or a decrease
in antiangiogenic activity. Although it has
not been clearly demonstrated, hypoxia is
probably the common primum movens: it
provokes the expression of hypoxia-
inducible factor-1α (HIF-1α), which, after
binding with HIF-1β, becomes an active
molecule (HIF-1) capable of promoting the
expression of several genes6 including
VEGF-A, platelet-derived growth factor
(PDGF), stromal cell-derived growth fac-
tor-1 (SDF-1), and placental growth factor
(PIGF).
Challenges to current therapeu-
tic strategies
Despite the success of anti-VEGF-A
drugs, modifications and improvements in
the management of nAMD are still warrant-
ed in relation to several aspects.
Treatment regimens and follow-
up frequency
The treatment of nAMD requires
repeated injections and long-term, frequent
follow-up. Different treatment schedules
have been designed in order to reduce the
treatment burden. The most commonly used
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ones are the pro-re-nata (PRN) and the
treat-and-extend regimens.7-8
Analysis of the CATT and the IVAN tri-
als shows that monthly administration has a
better effect on vision than an as needed
approach,9-10 although clinicians have not
yet reached a consensus regarding the best
treatment regimen. Nevertheless, there is
evidence that shorter injection intervals lead
to better visual outcome and steady anatom-
ic improvements. The high costs of frequent
anti-VEGF-A drug injections and of a strict
regimen of follow-up visits render the treat-
ment of nAMD financially burdensome.
Complications
Although it is widespread as a tech-
nique, the practice of intravitreal injection is
not completely free of complications. The
intravitreal injection of anti-VEGF-A drugs
is related to many adverse events, such as
subconjunctival hemorrhages, retinal tears
and retinal detachments, vitreous hemor-
rhages, retinal vascular occlusion, increase
of intraocular pressure, cataract, tachyphy-
laxis, intraocular inflammation and endoph-
thalmitis.11-14
Blockage of the VEGF-A pathway itself
seems to have potentially negative effects
on retinal trophism, due to the role that
VEGF-A may play in the maintenance of
the choriocapillaris, Müller cells and pho-
toreceptors.15 Long-term intravitreal injec-
tion of anti-VEGF-A drugs has been corre-
lated with the possible progression of areas
of geographic atrophy in patients with
nAMD.16
Visual loss despite anti-vascular
endothelial growth factor A ther-
apy
Inadequate response to anti-VEGF-A
drugs is, unfortunately, a common finding
and much CNV remains active despite a
protocol of frequent and timely injections.
The SEVEN-UP study showed that, approx-
imately 7 years after ranibizumab therapy in
the ANCHOR and MARINA trials, one
third of patients demonstrated good visual
outcomes, whereas another third had poor
visual outcomes.17 The causes for resistance
to anti-VEGF-A therapy are hypothesized
to be various: mechanisms of tolerance,
tachyphylaxis, compensation by other
angiogenic factors, changes in vascular
architecture, sustained activation of the
complement system, as well as inflammato-
ry response, misdiagnosis and genetic vari-
ants.18
Future directions: a focus on new
molecular targets
Considering the unresolved problems
connected to the current management of
patients affected by nAMD, many efforts
are being made worldwide in order to
design new therapeutic approaches to this
multifactorial pathology. It is not the aim of
this contribution to discuss new drug deliv-
ery methods, which nonetheless represent a
very promising field of interest and a valu-
able potential source of improvement for
the current therapeutic strategies. The pur-
pose of this review is to briefly review the
promising new molecular targets for neoan-
giogenesis (Figure 1), inflammation or
fibrosis inhibition (Figure 2), that could rep-
resent a potential resource in the treatment
of nAMD and the related drugs in various
stages of development (Table 1).
Other antagonists to the vascular
endothelial growth factor A pathway
- Designed ankyrin repeat protein family
(DARPin). Designed ankyrin repeat
proteins are small, single-domain pro-
teins that can selectively bind to a target
protein with a higher level of affinity
and specificity than an antibody.
Abicipar pegol (Allergan), previously
known as MP0112, is a recombinant
protein of the designed ankyrin repeat
protein family. It binds to all isoforms
of VEGF-A in a similar manner to the
currently used anti-VEGF-A agents, but
with a higher affinity. A phase II ran-
domized double-blind clinical trial
(ClinicalTrials.gov identifier:
NCT02181517) evaluated abicipar
pegol for AMD compared to ranibizum-
ab. The first results from the phase II
study have already been published19:
patients received abicipar pegol every
month for 3 months, while the control
group received ranibizumab monthly
for the entire duration of the study. The
study was not powered enough to show
statistically significant differences
between the two drugs, but it showed
good results in terms of the efficacy and
durability of abicipar pegol. A phase III
study evaluating the safety and efficacy
of abicipar pegol in patients with
nAMD is ongoing (ClinicalTrials.gov
identifier: NCT02462486).
- TH258. RTH258 (formerly ESBA1008)
is a humanized single chain antibody
fragment that inhibits all isoforms of
VEGF-A. It is a smaller anti-VEGF-A
agent than ranibizumab or aflibercept
and, because of its high stability and
solubility, it is possible to concentrate
RTH258 up to 120 mg/mL, allowing the
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Figure 1. Schematic representation summarizing the antiangiogenic therapy drugs and
their targets. See text for details.
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administration of 6 mg in a single 50-
µL intravitreal injection. This enables
the delivery of a much higher molar
dose in the same volume as the current
VEGF-A inhibitors in clinical use,
potentially supporting the early initia-
tion and prolonged duration of the
effects of treatment. Animal studies
have shown that the small size of
RTH258 leads to faster systemic clear-
ance and lower systemic exposure com-
pared to anti-VEGF-A agents such as
ranibizumab and bevacizumab. The
smaller size may also allow for better
ocular tissue penetration.20-21 A six-
month phase I/II prospective multicen-
ter double-masked and randomized
clinical trial demonstrated non-inferior-
ity in the change in central subfield
thickness at 1 month for the 4.5- and
6.0-mg RTH258 doses compared to
ranibizumab, and an increase of 30 days
in the median time to retreatment for the
6.0-mg dose.22 A phase III clinical trial
comparing the efficacy and safety of
RTH258 versus aflibercept in subjects
with nAMD is ongoing
(ClinicalTrials.gov identifier:
NCT02307682).
- Sphingosine-1-phosphate (S1P) anti-
body. S1P is a bioactive lipid mediator
whose biological activities are moderat-
ed by the surface receptors found on
endothelial cells. Retinal pigment
epithelium (RPE) may release and store
S1P in the retina and could contribute to
the pathological angiogenesis, vascular
permeability, fibrosis and inflammatory
responses associated with nAMD.23
Sonepcizumab, a monoclonal antibody
that selectively binds to S1P, was evalu-
ated in animal models with oxygen-
induced ischemic retinopathy and was
found to cause a decreased inflow of
macrophages into the retina, the sup-
pression of retinal NV, and reduced
CNV after laser disruption of Bruch’s
membrane.23 iSONEP (LPath, Inc, San
Diego, CA, USA), the ocular formula-
tion of sonepcizumab, was evaluated in
a phase II clinical trial which did not
meet its primary or key secondary end-
points. nAMD patients who had not
responded adequately to existing anti-
VEGF-A therapies, including Lucentis,
Avastin and Eylea, did not show any
statistically significant improvement in
visual acuity when treated with
iSONEP as an adjunctive or sole thera-
py (ClinicalTrials.gov identifier:
NCT01414153).
- Squalamine lactate. Squalamine is a
small molecule derived from the carti-
lage of the dogfish shark (Squalus acan-
thias), which acts against the develop-
ment of aberrant NV, by inhibiting
downstream signaling pathways of mul-
tiple growth factors, including VEGF-
A, PDGF and basic fibroblast growth
factor (bFGF). A phase III clinical trial
evaluating the efficacy and safety of
ophthalmic squalamine lactate solution
0.2% (OHR-102, Ohr Pharmaceuticals,
New York, NY), administered twice
daily in association with intravitreal
ranibizumab, is currently recruiting
patients (ClinicalTrials.gov identifier:
NCT02727881).
- Small interfering RNA (siRNA). With
the aim of down-regulating the produc-
tion of VEGF-A and the activity of
VEGF receptors (VEGFRs), siRNA
technology has been tested for the treat-
ment of AMD. siRNA are short RNA
molecules that, once incorporated into
the RNA-induced silencing complex,
are able to guide the degradation of spe-
cific mRNAs. Naked siRNAs targeting
VEGF-A (bevasiranib, Opko Health
Inc., Miami, FL, USA) or one of its
receptors, VEGFR1 (AGN 211745, pre-
viously siRNA-027; Allergan Inc.,
Irvine, CA, USA), were administered
intravitreously and tested as drug candi-
dates in clinical trials for CNV due to
AMD. The preliminary safety data of
these two compounds were encourag-
ing, but they failed to meet key efficacy
parameters in further studies.24
Platelet-derived growth factor
inhibition
In vitro studies have demonstrated the
role of PDGF in the process of angiogene-
sis.25 It has been shown to promote the
migration and proliferation of endothelial
cells, as well as an increase in the recruit-
ment of pericytes, which have been demon-
strated to play a central role in protecting
the endothelial cells against VEGF-A inhi-
bition.26
The involvement of PDGF in the ocular
NV process has been demonstrated27 and
seems to be related to the entry of platelets
and monocytes into the vitreous and sub-
retinal space upon injury to the blood-retina
barrier, with subsequent platelet aggrega-
tion and PDGF discharge. Interleukins such
as IL-1 and TGF-β released from activated
macrophages may cause further synthesis
and release of PDGF.
- Fovista. Ophthotech (New York,
U.S.A.) has developed a high affinity
                             Review
Figure 2. Schematic representation summarizing the anti-inflammatory and anti-fibrotic
therapy drugs and their targets. See text for details.
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PDGF antagonist called E10030
(Fovista). This molecule binds to PDGF
and prevents it from binding to its
receptor PDGFR-β. In vitro/in vivo
studies using this compound have
shown its effectiveness, in combination
with an anti-VEGF-A agent, in prevent-
ing the formation of CNV, as well as in
stripping pericytes from vessels that
have already formed, leading to their
regression. Phase-I and phase-II clinical
trials investigating the safety and toler-
ability, and safety and efficacy, of
intravitreal injection of Fovista in
humans, respectively in combination
with anti-VEGF-A agents or as a
monotherapy, have been completed,
showing Fovista as a possible future
therapeutic agent when used in combi-
nation with anti-VEGF-A drugs
(Clinical Trials.gov identifier:
NCT00569140) (ClinicalTrials.gov
identifier: NCT01089517). Two phase-
III, randomized, double-blind clinical
trials evaluating the safety and efficacy
of the intravitreous administration of
Fovista in combination with ranibizum-
ab, compared to ranibizumab monother-
apy, have recently been terminated
(ClinicalTrials.gov identifier:
NCT01944839) (ClinicalTrials.gov
identifier: NCT01940900).
Unfortunately, Ophthotech Corporation
announced that the addition
of Fovista to a monthly Lucentis regi-
men did not result in benefit as meas-
ured by the mean change in visual acu-
ity at the 12 month time point.
Tyrosine kinase inhibition
Since, as suggested by recent research,
the activity of VEGF-A and other angio-
genic factors is regulated by tyrosine kinas-
es, kinase inhibitors may be used to target
VEGFRs. The high homology between
VEGFRs and PDGFRs allows many kinase
inhibitors to simultaneously block both.28
- Axitinib. Axitinib is a multi-receptor
tyrosine kinase inhibitor that has
marked inhibitory effects on VEGFR2,
PDGFR-β and c-KIT receptors.
Axitinib is currently approved for use in
advanced human renal cell carcinoma.
Because of its anti-VEGFR and anti-
PDGFR-β action, its use in nAMD
treatment has been suggested. It recent-
ly showed good efficacy at a low dose
in a laser-induced CNV model in rats.29
- Pazopanib. Pazopanib (GlaxoSmithKline,
Brentford, UK) (GW786034) is a small
molecule that has been investigated as an
eye drop in CNV, due to its ability to act as
an inhibitor of VEGFRs 1, 2, and 3;
PDGF-α and β; and the stem cell factor
receptor c-KIT.30-34 A multi-country, ran-
domized, double-masked, dose-ranging
study phase IIb clinical trial was complet-
ed in 2015. It demonstrated the inferiority
of daily pazopanib eye drops compared to
intravitreal injection of ranibizumab in the
treatment of nAMD.35
- Regorafenib. Regorafenib (Bayer
Healthcare, Leverkusen, Germany) is an
eye drop multikinase inhibitor (MKI)
which targets several angiogenic kinas-
es, including VEGFR-2, VEGFR-1,
VEGFR-3, fibroblast growth factor
receptor 1 (FGFR1), PDGFR-β and the
mutant oncogenic kinases c-KIT, RET
and B-RAF. It showed positive results
in a phase I clinical trial in healthy vol-
unteers and a phase II clinical trial is
currently in progress.36
- Pan 90806. Pan 90806 (PanOptica) is a
MKI of VEGFR-2, FGFR1-3, TIE2,
and of the autophosphorylation of other
pro-angiogenic tyrosine kinase recep-
tors. This molecule was initially investi-
gated as an oral antineoplastic agent but
showed poor results. Subsequently it
was adopted as an eye drop for AMD
and diabetic retinopathy, since it is a
small molecule with high permeability
and has the ability to concentrate high
doses in the active form at the posterior
pole. Phase I/II studies are currently
ongoing (ClinicalTrials.gov identifier:
NCT02022540). 
- Sorafenib. Sorafenib is an oral MKI
whose antiangiogenic action inhibits
VEGFR-1, -2, and -3, as well as
PDGFR-β, RAF kinase and c-KIT.37 In
a study using a mouse model of CNV,
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Table 1. Approved and not-yet-approved drugs for age-related macular degeneration
treatment.
Drug                       Type of molecule                                   Target                      Clinical trial
Drug                                   Type of molecule                                                 Target                                Clinical trial
Bevacizumab                Monoclonal antibody                                             VEGF-A                                 Approved
Aflibercept              Chimeric soluble receptor                                   VEGF-A/PlGF                            Approved
Conbercept             Chimeric soluble receptor                                        VEGF-A                                 Approved
Ranibizumab            Fab fragment of antibody                                         VEGF-A                                 Approved
Pegaptanib                      Pegylated aptaner                                                VEGF-A                                 Approved
Abicipar                        Single-domain protein                                           VEGF-A                                  Phase III
RTH258                Single-Chain Antibody Fragment                    VEGF-A  (all isoforms)                    Phase III
Axitinib                               Small molecule                                  VEGFR-2/PDGFR-β/c-KIT                  PhaseI/II
Pazopanib                          Small molecule                             VEGFR-1,2,3/PDGFRα,β, c-KIT             Phase II
Regorafenib                      Small molecule                   VEGFR-1,2,3/c-KIT/PDGFRβ/FGFR1/MAPK   Phase II
Pan 90806                           Small molecule                               VEGFR-1,2,3/TIE2/FGFR1,2,3              Phase I/II
Sorafenib                           Small molecule                           VEGFR-1,2,3/c-KIT/PDGFRβ/RAF            Phase II
Sonepcizumab             Monoclonal antibody                                                 S1P                                      Phase II
Squalamine                        Small molecule                                            proton pumps                            Phase III
Fovista                             Pegylated Aptamer                                                 PDGF                                   Phase III
AdGVPEDF.11D                adenoviral vector                                       PEDF expression                          Phase I
ATG003                                Small molecule                                  nAchR/PEDF expression                   Phase II
JSM6427                             Small molecule                                           αvβ1 integrins                            Phase I
Volociximab         Chimeric monoclonal antibody                              α5β1 integrin                             Phase I
ALG-1001                              Oligopeptide                             α5β1, αvβ3 and αvβ5 integrins            Phase I
Infliximab                      Monoclonal antibody                                              TNF-α                                   Phase II
POT-4                                    Oligopeptide                                            Complement C3                           Phase I
Sirolimus                           Small molecule                                                   mTOR                                    Phase II
Palomid 529                       Small molecule                                                 mTORC1                                  Phase I
PF-04523655                               siRNA                                                RTP801 expression                        Phase II
RXI-109                                     sd-rxRNA                                              CTGF expression                          Phase I
hI-con1                              Chimeric protein                                           Tissue factor                             Phase II
VEGF-A, vascular endothelial growth factor A; PlGF, placental growth factor; VEGFR, vascular endothelial growth factor receptor; PDGF, platelet
derived growth factor; PDGFR, platelet derived growth factor receptor; FGFR, fibroblast growth factor receptor; KIT, v-kit feline sarcoma viral
oncogene homolog; RAF, v-raf-1 murine leukemia viral oncogene homolog 1; TIE, TEK tyrosine kinase endothelial; MAPK, mitogen-activated pro-
tein kinase; PEDF, Pigment epithelium-derived factor; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; TNF-α, Tumor necrosis
factor; S1P, Sphingosine-1-phosphate; nAChR, Nicotinic acetylcholine receptor; C3, Component 3.
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sorafenib showed the ability to decrease
the extent of CNV in a dose-dependent
manner.38 In two case reports, sorafenib
was administered orally in combination
with intravitreal anti-VEGF-A treat-
ment and all patients appeared to gain
some benefit.39-40
Pigment epithelium-derived factor 
PEDF is a cell survival factor secreted
by the RPE, widely expressed in the central
and peripheral nervous system,41,42 and
apparently an endogenous inhibitor of
angiogenesis in the eye.43 A critical balance
appears to exist between PEDF and VEGF-
A, with PEDF counteracting the angiogenic
potential of VEGF-A. A physiological
decrease in PEDF occurring in the elderly
may disrupt this balance and create a per-
missive environment for the formation of
CNV in AMD.44 PEDF gene polymor-
phisms may also contribute to AMD.45
- ATG003. PEDF protein expression has
been found to be decreased in RPE from
smoker patients with AMD compared to
controls.46 It has also been reported that
nicotine, a potent angiogenic agent,
increased the VEGF-A/PEDF ratio in
the RPE through nicotinic acetylcholine
receptor (nAchR).47 ATG003
(CoMentis, formerly Athenagen, South
San Francisco, CA, USA) is a topical
mecamylamine that antagonizes the
nAchR pathway which mediates angio-
genesis. It was designed as an eye drop
therapy for AMD, and phase II clinical
trials testing its safety and efficacy were
completed in 2010 (ClinicalTrials.gov
identifier: NCT00414206)
(Clinicaltrials.gov identifier:
NCT00607750), although no results
have been published yet.
- AdGVPEDF.11D. An adenoviral vector
containing complementary DNA encod-
ing human PEDF, known as
AdGVPEDF.11D (GenVec, Inc.,
Gaithersburg, MD, USA), seems to
allow the expression of large amounts of
PEDF in the target tissue and inhibit ocu-
lar NV in murine AMD models.48
Intravitreal injection of AdGVPEDF.11D
results in the local production of PEDF.
A phase I single-dose trial enrolled 28
patients with severe nAMD.49 This clini-
cal study suggested that antiangiogenic
activity may last for up to 6 months after
a single intravitreous injection, since half
of the lesions treated did not change in
size from baseline. However, no further
studies have corroborated this hypothe-
sis.
Integrin receptor antagonists
Integrins are transmembrane proteins
that mediate the attachment between cells
and the surrounding extracellular matrix.
Their ligands are fibronectin, vitronectin,
collagen and laminin.50 Integrins localized
at the apical surface of RPE bind to ligands
in the interphotoreceptor matrix51 and par-
ticipate in the interactions between photore-
ceptors and the RPE.52 During aging, the
dissociation between the interphotoreceptor
matrix and retinal cells seems to contribute
to decreasing the supply of oxygen, nutri-
ents and growth factors from the choroidal
or retinal vessels, as well as to inhibit the
phagocytosis of photoreceptor outer seg-
ments.53 It has been shown that α5β1, αvβ3
and αvβ5 integrins are expressed in CNV
tissue,54 and many studies have demonstrat-
ed a possible role for their antagonists in
preventing ocular NV.55-59
- SM6427. JSM6427 is a small molecule
antagonist of the α5β1 integrin, which
has been shown to inhibit retinal and
CNV in preclinical models.60 A phase I
clinical trial of JSM6427 for nAMD has
been completed (ClinicalTrials.gov
identifier: NCT00536016). Although
encouraging results were obtained, no
further studies have evaluated
JSM6427.
- Volociximab. Volociximab (Ophthotech
Corporation, Princeton, NY, USA) is a
chimeric monoclonal antibody specifi-
cally blocking the binding of
fibronectin to the α5β1 integrin. A phase
I study evaluating the safety of intravit-
real volociximab combined with
ranibizumab for nAMD
(ClinicalTrials.gov identifier:
NCT00782093) revealed good
improvements in visual acuity at nine
weeks, although the results did not dis-
tinguish the independent contributions
of ranibizumab and volociximab.
- ALG-1001. ALG-1001, also known as
Lu minate (Allegro Ophthalmics, San
Juan Capistrano, CA, USA), is a syn-
thetic oligopeptide that targets α5β1,
αvβ3 and αvβ5 integrins. It has been
investigated for 3 indications: nAMD,
diabetic macular edema and vitreomac-
ular traction. In a phase Ib clinical trial
ALG-1001 used in combination with
ranibizumab for the treatment of nAMD
the drug was found to be safe.61
Anti-inflammatory and anti-
immune therapies
Over the last few years many authors
have identified inflammatory mechanisms
and immune responses as central features in
all AMD phenotypes, consolidating the
hypothesis that AMD is a singular disease
with multiple outcomes.62-64
Investigating the role of immune
response in the pathogenesis of ocular NV
may therefore represent a promising field in
the search for new targets for AMD treat-
ments (Figure 2).
- Infliximab. Tumor necrosis factor alpha
(TNF-α) plays a central role in inflamma-
tion, apoptosis and immune reactions. The
anti-TNF-α monoclonal antibody inflix-
imab (Remicade, Centocor, Inc.,
Horsham, PA, USA) is commonly used to
treat various inflammatory diseases.
Intravitreal infliximab has been reported to
inhibit laser-induced CNV in rats and has
been safely administered up to a dose of
2 mg in the rabbit eye.65-66 Intravitreal
infliximab was also administered to three
patients with nAMD, resulting in
improved visual acuity and central foveal
thickness on Optical Coherence
Tomography (OCT).67
- POT-4. The alternative complement
pathway has also been implicated in the
development of AMD.68 POT-4 is a
potent inhibitor of complement factor
C3 activation. A phase I clinical trial
was designed to evaluate the safety and
tolerability of POT-4 administered via
intravitreal injections
(ClinicalTrials.gov identifier:
NCT00473928). Preliminary results
indicated that intravitreal POT-4 is safe
and well-tolerated and supported its
administration in larger randomized
clinical trials in order to further define
its efficacy profile. Even though no sig-
nificant improvement in visual acuity
was observed, there was no significant
visual loss either.69
- Sirolimus. Mammalian target of
rapamy cin (mTOR) is an evolutionarily
conserved serine/threonine kinase
which appears to function as a central
node in a signaling cascade directing
the integration of diverse environmental
inputs into the immune microenviron-
ment.70 Sirolimus (previously known as
rapamycin, Santen Pharmaceutical,
Inc., Osaka, Kapan, and MacuSight,
Inc., Union City, CA) was discovered in
the 1970s as a soil bacterium metabo-
lite. It was collected on Easter Island
(Rapa Nui) and was originally devel-
oped as a macrolide antifungal agent.
Subsequently, it was found to possess
potent immunosuppressive and antipro-
liferative properties due to its ability to
bind to the protein FKBP12. The result-
ing sirolimus-FKBP12 complex binds
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to and inhibits mTOR.71 It is used as an
anticancer drug against several solid
tumors and an immunosuppressive
agent in the transplantation of various
organs, especially kidneys.72 Preclinical
studies in experimental models have
shown promising results regarding the
use of this pharmacological agent to
inhibit ocular neoangiogenesis.73-74
Early phase I/II studies have subse-
quently provided encouraging safety
and efficacy data (ClinicalTrials.gov
identifier: NCT00712491). A phase II
study (EMERALD) of an ocular
sirolimus (rapamycin) formulation in
combination with ranibizumab in
patients with AMD has been terminat-
ed: the last update was in June 2013
(ClinicalTrials.gov identifier:
NCT00766337). 
- Palomid 529. Unlike Sirolimus, which
binds to mTOR Complex 1 (mTORC1),
Palomid 529 is capable of blocking both
mTORC1 and mTORC2. A phase I clin-
ical trial enrolled five participants with
nAMD who were refractory to intravit-
real anti-VEGF-A, and received three
consecutive monthly subconjunctival
doses of 1.9 mg Palomid 529.
Unfortunately, compared to baseline no
clinically important changes were
observed in best-corrected visual acuity,
fluorescein leakage pattern, CNV size at
indocyanine green angiography, or aut-
ofluorescence patterns at fundus auto-
fluorescence.75
- PF-04523655. PF-04523655 is a 19-
ribo nucleotide double-stranded siRNA
which inhibits the expression of the
hypoxia-inducible gene, RTP801, an
inhibitor mTOR signaling.76 A single
intrevitreal injection of PF-0523655
≤3000 mg seemed to be safe and well-
tolerated in a phase I study involving 27
patients with AMD which had been
unresponsive to prior treatment.77 A
phase II clinical trial, the multicenter
and randomized MONET study, sought
to prove the efficacy of PF-04523655 in
combination with Lucentis. It demon-
strated the superiority of PF-
04523655+ranibizumab over
ranibizumab monotherapy in terms of
best corrected visual acuity improve-
ment.78
Connective tissue growth factor
inhibition
The 38-KDa cysteine-rich polypeptide
connective tissue growth factor (CTGF),
which has a pleiotropic and cell type-specif-
ic role, was first isolated in human umbili-
cal vein endothelial cells.79 CTGF is consid-
ered to be involved in the pathological syn-
thesis of peri-retinal fibrous tissue in AMD
patients.80
- RXI-109. RXI-109 (RXi Pharmaceuticals,
Marlborough, MA) is a self-delivering
RNAi compound (sd-rxRNA), designed
to reduce the expression of CTGF and
developed to reduce dermal scarring fol-
lowing planned surgery. A study designed
to evaluate the safety, tolerability and clin-
ical activity of RXI-109 administered by
intravitreal injection, in order to reduce the
progression of subretinal fibrosis in sub-
jects with advanced nAMD degeneration,
is currently recruiting patients
(ClinicalTrials.gov identifier:
NCT02599064).
Tissue factor inhibition
Tissue factor (TF) is expressed in neovascu-
lar endothelium but not in the normal
vasculature of mouse and pig models.
- hI-con1. Factor VII-verteporfin has
been tested with the aim of improving
the therapeutic results of photodynamic
therapy in rats, due to its ability to bind
tightly and specifically to TF, which is
expressed in the endothelial cells of
CNV but not in the normal vascula-
ture.81 hI-con1 (Iconic Therapeutics Inc.
South San Francisco, CA, USA), a syn-
thetic molecule composed of factor VII
conjugated to an antibody Fc, binds to
TF and selectively destroys pathologic
blood vessels.  A phase II, randomized,
double-masked, multi-center study
evaluating the administration of repeat-
ed intravitreal injections of hI-con1 in
patients with CNV secondary to AMD
has recently been completed and the
results are pending (ClinicalTrials.gov
identifier: NCT02358889).
CD93
Human CD93 is a 652 amino acid sur-
face glycoprotein with a predicted molecu-
lar mass of 68 kDa; it is rich in proline and
charged amino acids.82-83 CD93 expression
has been found in several cell types, includ-
ing the vascular endothelium.84-85 Moreover,
the soluble EGF-like domain of CD93,
which is the product of ectodomain cleav-
age or shedding, has recently been discov-
ered to be an angiogenic factor.86 The mon-
oclonal antibody 4E1, binding to CD93, is
capable to selectively inhibit blood vessel
formation both in vitro and in vivo, without
affecting endothelial cell survival.87
CD93 expression has recently been
observed in the endothelial cells of AMD-
related CNV and the soluble CD93 domain
has been shown to be overexpressed in the
aqueous humor of AMD patients, suggest-
ing that CD93 may represent a potential
new antiangiogenic target in the treatment
of CNV.88
HTRA1
HTRA1 is a serine protease involved in
protein quality control and cell fate.
HTRA1 expression has been found to be
significantly higher in CNV patients com-
pared to controls. After treatment with anti-
VEGF-A, it returned to control levels.89 The
ability of HTRA1 to regulate extracellular
matrix proteoglycan degradation and TGF-
β activity appears to allow it to modulate
AMD development.90-91 HTRA1 can be
considered an innovative target. This
hypothesis is supported by the discovery of
the antibody 94, which is an inhibitor of this
protein.92
Conclusions
Over the last decade, the management
of AMD has changed significantly due to
the advent of anti-VEGF-A therapy.
However, treatment with anti-VEGF-A
agents rarely brings about an improvement
in visual acuity. The study of the patho-
genetic mechanisms of this disease has led
to the discovery of several proteins and fac-
tors, which could be used as new molecular
targets in AMD therapy.
A great effort has been made to inhibit
neoangiogensis with several drugs now in
advanced clinical trials (Figure 1) targeting
new antigens with complementary func-
tions, which could offer novel opportunities
to circumvent resistance mechanisms and
improve the anti-VEGF-A therapy. 
The unsuccessful outcomes of the anti-
VEGF-A therapy have often been attributed
to development of subretinal fibrosis and
inflammatory response. Other interesting
drugs seem to come from these fields of
research (Figure 2), with at least four com-
pounds in clinical phase II (Infliximab,
Sirolimus, PF-04523655 and hI-con1).
Future directions in AMD treatment
will have to focus now on applying combi-
nations of drugs with different angiogenic
and non-angiogenic targets, with the aim of
achieving disease stabilization or regres-
sion, improving visual acuity, and shorten-
ing injection intervals.
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